Literature DB >> 18075287

Critical assessment of the current guidelines for the management and treatment of morbidly obese patients.

B Burguera1, A Agusti, P Arner, A Baltasar, F Barbe, A Barcelo, I Breton, T Cabanes, F F Casanueva, M E Couce, C Dieguez, M Fiol, J M Fernandez Real, X Formiguera, G Fruhbeck, M Garcia Romero, M Garcia Sanz, E Ghigo, R Gomis, K Higa, O Ibarra, A Lacy, A Larrad, L Masmiquel, V Moizé, B Moreno, J Moreiro, W Ricart, M Riesco, R Salinas, J Salvador, F X Pi-Sunyer, N Scopinaro, L Sjostrom, A Pagan, V Pereg, A Sánchez Pernaute, A Torres, J R Urgeles, A Vidal-Puig, J Vidal, M Vila.   

Abstract

An interdisciplinary panel of specialists met in Mallorca in the first European Symposium on Morbid Obesity entitled; "Morbid Obesity, an Interdisciplinary Approach". During the two and half days of the meeting, the participants discussed several aspects related to pathogenesis, evaluation, and treatment of morbid obesity. The expert panel included basic research scientists, dietitians and nutritionists, exercise physiologists, endocrinologists, psychiatrists, cardiologists, pneumonologists, anesthesiologists, and bariatric surgeons with expertise in the different weight loss surgeries. The symposium was sponsored by the Balearic Islands Health Department; however, this statement is an independent report of the panel and is not a policy statement of any of the sponsors or endorsers of the Symposium. The prevalence of morbid obesity, the most severe state of the disease, has become epidemic. The current recommendations for the therapy of the morbidly obese comes as a result of a National Institutes of Health (NIH) Consensus Conference held in 1991 and subsequently reviewed in 2004 by the American Society for Bariatric Surgery. This document reviews the work-up evaluation of the morbidly obese patient, the current status of the indications for bariatric surgery and which type of procedure should be recommended; it also brings up for discussion some important real-life clinical practice issues, which should be taken into consideration when evaluating and treating morbidly obese patients. Finally, it also goes through current scientific evidence supporting the potential effectiveness of medical therapy as treatment of patients with morbid obesity.

Entities:  

Mesh:

Year:  2007        PMID: 18075287     DOI: 10.1007/BF03349226

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  39 in total

Review 1.  Bariatric surgery for morbid obesity: health implications for patients, health professionals, and third-party payers.

Authors:  Henry Buchwald
Journal:  J Am Coll Surg       Date:  2005-04       Impact factor: 6.113

2.  Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.

Authors:  Lars Sjöström; Anna-Karin Lindroos; Markku Peltonen; Jarl Torgerson; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Bo Larsson; Kristina Narbro; Carl David Sjöström; Marianne Sullivan; Hans Wedel
Journal:  N Engl J Med       Date:  2004-12-23       Impact factor: 91.245

3.  Randomized trial of lifestyle modification and pharmacotherapy for obesity.

Authors:  Thomas A Wadden; Robert I Berkowitz; Leslie G Womble; David B Sarwer; Suzanne Phelan; Robert K Cato; Louise A Hesson; Suzette Y Osei; Rosalind Kaplan; Albert J Stunkard
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

4.  The disease burden associated with overweight and obesity.

Authors:  A Must; J Spadano; E H Coakley; A E Field; G Colditz; W H Dietz
Journal:  JAMA       Date:  1999-10-27       Impact factor: 56.272

Review 5.  Obesity as a disease.

Authors:  R T Jung
Journal:  Br Med Bull       Date:  1997       Impact factor: 4.291

6.  Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial.

Authors:  T A Wadden; R I Berkowitz; D B Sarwer; R Prus-Wisniewski; C Steinberg
Journal:  Arch Intern Med       Date:  2001-01-22

7.  Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans.

Authors:  Camilla Holdstock; Britt Edén Engström; Margareta Ohrvall; Lars Lind; Magnus Sundbom; F Anders Karlsson
Journal:  J Clin Endocrinol Metab       Date:  2003-07       Impact factor: 5.958

8.  Serum ghrelin levels in response to glucose load in obese subjects post-gastric bypass surgery.

Authors:  Nicholas A Tritos; Edward Mun; Anne Bertkau; Rebecca Grayson; Eleftheria Maratos-Flier; Allison Goldfine
Journal:  Obes Res       Date:  2003-08

9.  Year-long weight loss treatment for obese patients with type II diabetes: does including an intermittent very-low-calorie diet improve outcome?

Authors:  R R Wing; E Blair; M Marcus; L H Epstein; J Harvey
Journal:  Am J Med       Date:  1994-10       Impact factor: 4.965

10.  Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters.

Authors:  Carel W le Roux; Simon J B Aylwin; Rachel L Batterham; Cynthia M Borg; Frances Coyle; Vyas Prasad; Sandra Shurey; Mohammad A Ghatei; Ameet G Patel; Stephen R Bloom
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

View more
  14 in total

1.  Consensus statements and bariatric surgery.

Authors:  Kamal K Mahawar; Sandeep Aggarwal; William R J Carr; Neil Jennings; Shlok Balupuri; Peter K Small
Journal:  Obes Surg       Date:  2015-06       Impact factor: 4.129

Review 2.  Recent advances in the modification of taste and food preferences following bariatric surgery.

Authors:  Stefany D Primeaux; Taniya de Silva; Tony H Tzeng; Monica C Chiang; Daniel S Hsia
Journal:  Rev Endocr Metab Disord       Date:  2016-06       Impact factor: 6.514

3.  Graft survival and complications after laparoscopic gastric banding for morbid obesity--lessons learned from a 12-year experience.

Authors:  Markus Naef; Wolfgang G Mouton; Ursula Naef; Oliver Kummer; Beat Muggli; Hans E Wagner
Journal:  Obes Surg       Date:  2010-09       Impact factor: 4.129

4.  Metabolic surgery is no longer just bariatric surgery.

Authors:  E Charles Moore; Walter J Pories
Journal:  Diabetes Technol Ther       Date:  2014-02       Impact factor: 6.118

5.  Urinary albumin excretion, HMW adiponectin, and insulin sensitivity in type 2 diabetic patients undergoing bariatric surgery.

Authors:  Sankar D Navaneethan; Karen R Kelly; Firas Sabbagh; Philip R Schauer; John P Kirwan; Sangeeta R Kashyap
Journal:  Obes Surg       Date:  2010-03       Impact factor: 4.129

6.  Acute effects of gastric bypass versus gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes.

Authors:  S R Kashyap; S Daud; K R Kelly; A Gastaldelli; H Win; S Brethauer; J P Kirwan; P R Schauer
Journal:  Int J Obes (Lond)       Date:  2009-12-22       Impact factor: 5.095

7.  Vertical Sleeve Gastrectomy Attenuates the Progression of Non-Alcoholic Steatohepatitis in Mice on a High-Fat High-Cholesterol Diet.

Authors:  Emily Whang; Yuan Liu; Shoichi Kageyama; Shih Lung Woo; Jieping Yang; Rupo Lee; Zhaoping Li; Haofeng Ji; Yijun Chen; Jerzy W Kupiec-Weglinski
Journal:  Obes Surg       Date:  2019-08       Impact factor: 4.129

8.  The FOXO1 Gene-Obesity Interaction Increases the Risk of Type 2 Diabetes Mellitus in a Chinese Han Population.

Authors:  Lilin Gong; Rong Li; Wei Ren; Zengchan Wang; Zhihong Wang; Maosheng Yang; Suhua Zhang
Journal:  J Korean Med Sci       Date:  2017-02       Impact factor: 2.153

Review 9.  Current treatment paradigms and emerging therapies for NAFLD/NASH.

Authors:  Sana Raza; Sangam Rajak; Aditya Upadhyay; Archana Tewari; Rohit Anthony Sinha
Journal:  Front Biosci (Landmark Ed)       Date:  2021-01-01

10.  Resting Metabolic Rate, Total Daily Energy Expenditure, and Metabolic Adaptation 6 Months and 24 Months After Bariatric Surgery.

Authors:  Bruce M Wolfe; Dale A Schoeller; Shelly K McCrady-Spitzer; Diana M Thomas; Chad E Sorenson; James A Levine
Journal:  Obesity (Silver Spring)       Date:  2018-03-31       Impact factor: 5.002

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.